Crystal Structure of the Mycobacterium tuberculosisβ-Ketoacyl-Acyl Carrier Protein Synthase III*

Mycolic acids (α-alkyl-β-hydroxy long chain fatty acids) cover the surface of mycobacteria, and inhibition of their biosynthesis is an established mechanism of action for several key front-line anti-tuberculosis drugs. In mycobacteria, long chain acyl-CoA products (C14–C26) generated by a type I fatty-acid synthase can be used directly for the α-branch of mycolic acid or can be extended by a type II fatty-acid synthase to make the meromycolic acid (C50–C56))-derived component. An unusual Mycobacterium tuberculosisβ-ketoacyl-acyl carrier protein (ACP) synthase III (mtFabH) has been identified, purified, and shown to catalyze a Claisen-type condensation between long chain acyl-CoA substrates such as myristoyl-CoA (C14) and malonyl-ACP. This enzyme, presumed to play a key role in initiating meromycolic acid biosynthesis, was crystallized, and its structure was determined at 2.1-Å resolution. The mtFabH homodimer is closely similar in topology and active-site structure to Escherichia coli FabH (ecFabH), with a CoA/malonyl-ACP-binding channel leading from the enzyme surface to the buried active-site cysteine residue. Unlike ecFabH, mtFabH contains a second hydrophobic channel leading from the active site. In the ecFabH structure, this channel is blocked by a phenylalanine residue, which constrains specificity to acetyl-CoA, whereas in mtFabH, this residue is a threonine, which permits binding of longer acyl chains. This same channel in mtFabH is capped by an α-helix formed adjacent to a 4-amino acid sequence insertion, which limits bound acyl chain length to 16 carbons. These observations offer a molecular basis for understanding the unusual substrate specificity of mtFabH and its probable role in regulating the biosynthesis of the two different length acyl chains required for generation of mycolic acids. This mtFabH presents a new target for structure-based design of novel antimycobacterial agents.

[1]  Talapady N. Bhat,et al.  Calculation of an OMIT map , 1988 .

[2]  W. Liu,et al.  Molecular cloning and sequencing of chicken liver fatty acid synthase cDNA. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[3]  D Alland,et al.  Thiolactomycin and Related Analogues as Novel Anti-mycobacterial Agents Targeting KasA and KasB Condensing Enzymes inMycobacterium tuberculosis * , 2000, The Journal of Biological Chemistry.

[4]  R. Heath,et al.  The 1.8 A crystal structure and active-site architecture of beta-ketoacyl-acyl carrier protein synthase III (FabH) from escherichia coli. , 2000, Structure.

[5]  S. Abdel-Meguid,et al.  Crystal structure of beta-ketoacyl-acyl carrier protein synthase III. A key condensing enzyme in bacterial fatty acid biosynthesis. , 1999, The Journal of biological chemistry.

[6]  D. Snider,et al.  The neglected global tuberculosis problem: a report of the 1992 World Congress on Tuberculosis. , 1994, The Journal of infectious diseases.

[7]  K. Bloch [10] Fatty acid synthases from Mycobacterium phlei , 1975 .

[8]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[9]  Mike Carson,et al.  RIBBONS 2.0 , 1991 .

[10]  R. Heath,et al.  Inhibition of β-Ketoacyl-Acyl Carrier Protein Synthases by Thiolactomycin and Cerulenin , 2001, The Journal of Biological Chemistry.

[11]  C. Rock,et al.  Acetoacetyl-acyl carrier protein synthase, a potential regulator of fatty acid biosynthesis in bacteria. , 1987, The Journal of biological chemistry.

[12]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[13]  C. Rock,et al.  Regulation of fatty acid biosynthesis in Escherichia coli. , 1993, Microbiological reviews.

[14]  T A Jones,et al.  Electron-density map interpretation. , 1997, Methods in enzymology.

[15]  S. Grzesiek,et al.  NMRPipe: A multidimensional spectral processing system based on UNIX pipes , 1995, Journal of biomolecular NMR.

[16]  K. Bloch Control mechanisms for fatty acid synthesis in Mycobacterium smegmatis. , 2006, Advances in enzymology and related areas of molecular biology.

[17]  C. Rock,et al.  Identification and substrate specificity of beta -ketoacyl (acyl carrier protein) synthase III (mtFabH) from Mycobacterium tuberculosis. , 2000, The Journal of biological chemistry.

[18]  James C. Sacchettini,et al.  Inactivation of the inhA-Encoded Fatty Acid Synthase II (FASII) Enoyl-Acyl Carrier Protein Reductase Induces Accumulation of the FASI End Products and Cell Lysis of Mycobacterium smegmatis , 2000, Journal of bacteriology.

[19]  Jorge Navaza,et al.  On the fast translation functions for molecular replacement , 1995 .

[20]  David A. Mead,et al.  Inhibition of a Mycobacterium tuberculosis β-Ketoacyl ACP synthase by isoniazid , 1998 .

[21]  K. A. Reynolds,et al.  Development of a scintillation proximity assay for beta-ketoacyl-acyl carrier protein synthase III. , 2000, Analytical biochemistry.

[22]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[23]  S J Wodak,et al.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. , 1999, Acta crystallographica. Section D, Biological crystallography.

[24]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[25]  Antoni R. Slabas,et al.  Molecular basis of triclosan activity , 1999, Nature.

[26]  Liang Tong,et al.  [34] Rotation function calculations with GLRF program. , 1997, Methods in enzymology.

[27]  Charles O. Rock,et al.  β-Ketoacyl-Acyl Carrier Protein Synthase III (FabH) Is a Determining Factor in Branched-Chain Fatty Acid Biosynthesis , 2000, Journal of bacteriology.

[28]  K. Reynolds,et al.  Characterization of β-Ketoacyl-Acyl Carrier Protein Synthase III from Streptomyces glaucescens and Its Role in Initiation of Fatty Acid Biosynthesis , 1998 .

[29]  S. Swaminathan,et al.  Risk of development of tuberculosis in HIV-infected patients. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[30]  H L Rieder,et al.  Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.

[31]  R. Slayden,et al.  Mycolic acids: structure, biosynthesis and physiological functions. , 1998, Progress in lipid research.

[32]  Sung-Hou Kim,et al.  Sparse matrix sampling: a screening method for crystallization of proteins , 1991 .

[33]  G J Kleywegt,et al.  Not your average density. , 1997, Structure.

[34]  R. Read,et al.  Improved Structure Refinement Through Maximum Likelihood , 1996 .

[35]  J. Jaworski,et al.  Purification and characterization of 3-ketoacyl-acyl carrier protein synthase III from spinach. A condensing enzyme utilizing acetyl-coenzyme A to initiate fatty acid synthesis. , 1992, The Journal of biological chemistry.

[36]  C. Sander,et al.  Errors in protein structures , 1996, Nature.

[37]  R. Read Improved Fourier Coefficients for Maps Using Phases from Partial Structures with Errors , 1986 .

[38]  R. Slayden,et al.  Isoniazid affects multiple components of the type II fatty acid synthase system of Mycobacterium tuberculosis , 2000, Molecular microbiology.